[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [Dyne Therapeutics, Inc. Common Stock](/topic/dyne-therapeutics) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Stage Analysis Screener Stage X Breakouts & Continuation Breakouts $BG $PZZA $ERIC $NSRGY $BKH $JBHT $BBY $ADC $PSA $DYN $LBRT $AVA $TRNO $DNLI $EDU Filters: Stage: 2A X 2B Stage Change: Stage Changed Market Cap: +Mini (over $300mln) WCR: Close in Upper Quarter of Bar Avg $ Volume: Over 100M Breakout: 13W Breakout Cross Above 13W High Sort order: Sector / Sub-industry The purpose of this scan is to find stocks attempting to breakout into Stage 2" [X Link](https://x.com/stageanalysis/status/1979566515440537958) [@stageanalysis](/creator/x/stageanalysis) 2025-10-18T15:13Z 38.3K followers, 2638 engagements "$10B.that is the combined market cap of major DM1 players $RNA $DYN and $PEPG; add to this $VRTX w/ a approach and stage similar to $PEPG. $RNA also prices in large FSHD opportunity. DM1 is one of the largest genetic disease categories larger than CF. Combined market cap could ultimately be $50B in 2029. There is also likely a succession of therapies coming onto market that improve on earlier approved drugs: 1) $RNA: most advanced evidence of fct improvements but probably least effective on molecular level (CASI) 2) $DYN: a year behind $RNA but CASI superior and impressive fct data at WMS25" [X Link](https://x.com/RNAiAnalyst/status/1978743257090642124) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-16T08:42Z 20.5K followers, 4746 engagements "Down-to-earth data-based discussion of $pepg's DM1 program safety and efficacy. $dyn $rna" [X Link](https://x.com/RNAiAnalyst/status/1978588482315378977) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-15T22:27Z 20.5K followers, 8592 engagements "$DYN Analyst price targets for tomorrow .🎯" [X Link](https://x.com/StewarT36463950/status/1978582096525316192) [@StewarT36463950](/creator/x/StewarT36463950) 2025-10-15T22:01Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Dyne Therapeutics, Inc. Common Stock
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Stage Analysis Screener Stage X Breakouts & Continuation Breakouts $BG $PZZA $ERIC $NSRGY $BKH $JBHT $BBY $ADC $PSA $DYN $LBRT $AVA $TRNO $DNLI $EDU Filters: Stage: 2A X 2B Stage Change: Stage Changed Market Cap: +Mini (over $300mln) WCR: Close in Upper Quarter of Bar Avg $ Volume: Over 100M Breakout: 13W Breakout Cross Above 13W High Sort order: Sector / Sub-industry The purpose of this scan is to find stocks attempting to breakout into Stage 2"
X Link @stageanalysis 2025-10-18T15:13Z 38.3K followers, 2638 engagements
"$10B.that is the combined market cap of major DM1 players $RNA $DYN and $PEPG; add to this $VRTX w/ a approach and stage similar to $PEPG. $RNA also prices in large FSHD opportunity. DM1 is one of the largest genetic disease categories larger than CF. Combined market cap could ultimately be $50B in 2029. There is also likely a succession of therapies coming onto market that improve on earlier approved drugs: 1) $RNA: most advanced evidence of fct improvements but probably least effective on molecular level (CASI) 2) $DYN: a year behind $RNA but CASI superior and impressive fct data at WMS25"
X Link @RNAiAnalyst 2025-10-16T08:42Z 20.5K followers, 4746 engagements
"Down-to-earth data-based discussion of $pepg's DM1 program safety and efficacy. $dyn $rna"
X Link @RNAiAnalyst 2025-10-15T22:27Z 20.5K followers, 8592 engagements
"$DYN Analyst price targets for tomorrow .🎯"
X Link @StewarT36463950 2025-10-15T22:01Z XXX followers, XX engagements
/topic/dyne-therapeutics/posts